Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11232474 | 0.72 | DRD2 (0.68) | MGLLHDAC6OPRM1OPRK1OPRD1 | |
| SCHEMBL22201266 | 0.72 | DDB1 (0.45) | — | |
| SCHEMBL22190368 | 0.72 | DDB1 (0.45) | — | |
| SCHEMBL8398287 | 0.71 | MGLL (0.68) | MGLLHDAC6OPRM1OPRK1OPRD1 | |
| SCHEMBL21002079 | 0.71 | MGLL (0.68) | MGLLHDAC6OPRM1OPRK1OPRD1 | |
| SCHEMBL26548204 | 0.71 | MGLL (0.68) | MGLLHDAC6OPRM1OPRK1OPRD1 | |
| SCHEMBL6977367 | 0.71 | CTSD (0.41) | — | |
| SCHEMBL6979908 | 0.70 | CTSD (0.43) | — | |
| SCHEMBL31674607 | 0.69 | DRD2 (0.68) | MGLLHDAC6OPRM1OPRK1OPRD1 | |
| SCHEMBL28368586 | 0.69 | DRD2 (0.68) | MGLLHDAC6OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1476429-A | EP4 receptor selective agonists in treatment of osteoporosis | �Ʒ� | 2004-02-18 | — | — | CN | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | MGLL 2314/4885HDAC6 4353/4885OPRM1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.